1887

Journal of General Virology header logo

Volume 81, Issue 10

Recombinant human monoclonal antibodies against different conformational epitopes of the E2 envelope glycoprotein of hepatitis C virus that inhibit its interaction with CD81 Free

Abstract

The antibody response to the envelope proteins of hepatitis C virus (HCV) may play an important role in controlling the infection. To allow molecular analyses of protective antibodies, we isolated human monoclonal antibodies to the E2 envelope glycoprotein of HCV from a combinatorial Fab library established from bone marrow of a chronically HCV-infected patient. Anti-E2 reactive clones were selected using recombinant E2 protein. The bone marrow donor carried HCV genotype 2b, and E2 used for selection was of genotype 1a. The antibody clones were expressed as Fab fragments in , and as Fab fragments and IgG1 in CHO cells. Seven different antibody clones were characterized, and shown to have high affinity for E2, genotype 1a. Three clones also had high affinity for E2 of genotype 1b. They all bind to conformation-dependent epitopes. Five clones compete for the same or overlapping binding sites, while two bind to one or two other epitopes of E2. Four clones corresponding to the different epitopes were tested as purified IgG1 for blocking the CD81–E2 interaction ; all four were positive at 0·3–0·5  μg/ml. Thus, the present results suggest the existence of at least two conserved epitopes in E2 that mediate inhibition of the E2–CD81 interaction, of which one appeared immunodominant in this donor.

  • Received:
  • Accepted:
  • Published Online:
© Microbiology Society
Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-81-10-2451
2000-10-01
2024-04-19
Loading full text...

Full text loading...

/deliver/fulltext/jgv/81/10/0812451a.html?itemId=/content/journal/jgv/10.1099/0022-1317-81-10-2451&mimeType=html&fmt=ahah

References

  1. Allander T., Beyene A., Jacobson S. H., Grillner L., Persson M. A. A. 1997; Patients infected with the same hepatitis C virus strain display different kinetics of the isolate-specific antibody response. Journal of Infectious Diseases 175:26–31
     [Google Scholar]
  2. Alter H. J., Purcell R. H., Shih J. W., Melpolder J. C., Houghton M., Choo Q. L., Kuo G. 1989; Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. New England Journal of Medicine 321:1494–1500
     [Google Scholar]
  3. Barbas C. F.III., Wagner J. 1995; Synthetic human antibodies: selecting and evolving functional proteins. Methods 8:94–103
     [Google Scholar]
  4. Barbas C. F.III., Kang A. S., Lerner R. A., Benkovic S. J. 1991; Assembly of combinatorial antibody libraries on phase surfaces: the gene III site. Proceedings of the National Academy of Sciences, USA 88:7978–7982
     [Google Scholar]
  5. Bjøro K., Froland S. S., Yun Z., Samdal H. H., Haaland T. 1994; Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. New England Journal of Medicine 331:1607–1611
     [Google Scholar]
  6. Burioni R., Plaisant P., Manzin A., Rosa D., Delli Carri V., Bugli F., Solforosi L., Abrignani S., Varaldo P. E., Fadda G., Clementi M. 1998; Dissection of human humoral immune response against hepatitis C virus E2 glycoprotein by repertoire cloning and generation of recombinant Fab fragments. Hepatology 28:810–814
     [Google Scholar]
  7. Burton D. R., Barbas C. F.III., Persson M. A. A., Koenig S., Chanock R. M., Lerner R. A. 1991; A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Proceedings of the National Academy of Sciences, USA 88:10134–10137
     [Google Scholar]
  8. Burton D. R., Pyati J., Koduri R., Sharp S. J., Thornton G. B., Parren P. W., Sawyer L. S., Hendry R. M., Dunlop N., Nara P. L. and others 1994; Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266:1024–1027
     [Google Scholar]
  9. Chanock R. M., Crowe J. E. Jr, Murphy B. R., Burton D. R. 1993; Human monoclonal antibody Fab fragments cloned from combinatorial libraries: potential usefulness in prevention and/or treatment of major human viral diseases. Infectious Agents and Disease 2:118–131
     [Google Scholar]
  10. Chomczynski P., Sacchi N. 1987; Single-step method of RNA isolation by acid guanidinium thiocyanate–phenol–chloroform extraction. Analytical Biochemistry 162:156–159
     [Google Scholar]
  11. Deleersnyder V., Pillez A., Wychowski C., Blight K., Xu J., Hahn Y. S., Rice C. M., Dubuisson J. 1997; Formation of native hepatitis C virus glycoprotein complexes. Journal of Virology 71:697–704
     [Google Scholar]
  12. Farci P., Alter H. J., Govindarajan S., Wong D. C., Engle R., Lesniewski R. R., Mushahwar I. K., Desai S. M., Miller R. H., Ogata N. and others 1992; Lack of protective immunity against reinfection with hepatitis C virus. Science 258:135–140
     [Google Scholar]
  13. Farci P., Alter H. J., Wong D. C., Miller R. H., Govindarajan S., Engle R., Shapiro M., Purcell R. H. 1994; Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proceedings of the National Academy of Sciences, USA 91:7792–7796
     [Google Scholar]
  14. Farci P., Shimoda A., Wong D., Cabezon T., De Gioannis D., Strazzera A., Shimizu Y., Shapiro M., Alter H. J., Purcell R. H. 1996; Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proceedings of the National Academy of Sciences, USA 93:15394–15399
     [Google Scholar]
  15. Feray C., Gigou M., Samuel D., Ducot B., Maisonneuve P., Reynes M., Bismuth A., Bismuth H. 1998; Incidence of hepatitis C in patients receiving different preparations of hepatitis B immunoglobulins after liver transplantation. Annals of Internal Medicine 128:810–816
     [Google Scholar]
  16. Flint M., Dubuisson J., Maidens C., Harrop R., Guile G. R., Borrow P., McKeating J. A. 2000; Functional characterization of intracellular and secreted forms of a truncated hepatitis C virus E2 glycoprotein. Journal of Virology 74:702–709
     [Google Scholar]
  17. Gauduin M. C., Parren P. W., Weir R., Barbas C. F., Burton D. R., Koup R. A. 1997; Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1. Nature Medicine 3:1389–1393
     [Google Scholar]
  18. Habersetzer F., Fournillier A., Dubuisson J., Rosa D., Abrignani S., Wychowski C., Nakano I., Trepo C., Desgranges C., Inchauspe G. 1998; Characterization of human monoclonal antibodies specific to the hepatitis C virus glycoprotein E2 with in vitro binding neutralization properties. Virology 249:32–41
     [Google Scholar]
  19. Ishii K., Rosa D., Watanabe Y., Katayama T., Harada H., Wyatt C., Kiyosawa K., Aizaki H., Matsuura Y., Houghton M., Abrignani S., Miyamura T. 1998; High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C. Hepatology 28:1117–1120
     [Google Scholar]
  20. Kabat E. A., Wu T. T., Perry H. M., Gottesman K. S., Foeller C. 1991 Sequences of Proteins of Immunological Interest , 5th edn. Bethesda, MD: U.S. Department of Health and Human Services;
  21. Kang A. S., Burton D. R., Lerner R. A. 1991; Combinatorial immunoglobulin libraries in phage lambda. Methods: A Companion to Methods in Enzymology 2:1111–1118
     [Google Scholar]
  22. Kato N., Sekiya H., Ootsuyama Y., Nakazawa T., Hijikata M., Ohkoshi S., Shimotohno K. 1993; Humoral immune response to hypervariable region 1 of the putative envelope glycoprotein (gp70) of hepatitis C virus. Journal of Virology 67:3923–3930
     [Google Scholar]
  23. Krawczynski K., Alter M. J., Tankersley D. L., Beach M., Robertson B. H., Lambert S., Kuo G., Spelbring J. E., Meeks E., Sinha S., Carson D. A. 1996; Effect of immune globulin on the prevention of experimental hepatitis C virus infection. Journal of Infectious Diseases 173:822–828
     [Google Scholar]
  24. Litwin S., Shlomchik M. 1990; A test for clonal relatedness in a set of lymphocytes. Journal of Experimental Medicine 171:293–297
     [Google Scholar]
  25. Parren P. W., Burton D. R., Sattentau Q. J. 1997; HIV-1 antibody – debris or virion?Nature Medicine. 3366–367
  26. Persson M. A. A., Caothien R. H., Burton D. R. 1991; Generation of diverse high-affinity human monoclonal antibodies by repertoire cloning. Proceedings of the National Academy of Sciences USA: 88:2432–2436
     [Google Scholar]
  27. Pileri P., Uematsu Y., Campagnoli S., Galli G., Falugi F., Petracca R., Weiner A. J., Houghton M., Rosa D., Grandi G., Abrignani S. 1998; Binding of hepatitis C virus to CD81. Science 282:938–941
     [Google Scholar]
  28. Rath S., Stanley C. M., Steward M. W. 1988; An inhibition enzyme immunoassay for estimating relative antibody affinity and affinity heterogeneity. Journal of Immunological Methods 106:245–249
     [Google Scholar]
  29. Rehermann B., Chang K. M., McHutchinson J., Kokka R., Houghton M., Rice C. M., Chisari F. V. 1996; Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients. Journal of Virology 70:7092–7102
     [Google Scholar]
  30. Reichard O., Norkrans G., Fryden A., Braconier J. H., Sönnerborg A., Weiland O. 1998; Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet 351:83–87
     [Google Scholar]
  31. Rosa D., Campagnoli S., Moretto C., Guenzi E., Cousens L., Chin M., Dong C., Weiner A. J., Lau J. Y., Choo Q. L., Chien D., Pileri P., Houghton M., Abrignani S. 1996; A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells. Proceedings of the National Academy of Sciences, USA 93:1759–1763
     [Google Scholar]
  32. Samuelsson A., Chiodi F., Öhman P., Putkonen P., Norrby E., Persson M. A. A. 1995; Chimeric macaque/human Fab molecules neutralize simian immunodeficiency virus. Virology 207:495–502
     [Google Scholar]
  33. Samuelsson A., Yari F., Hinkula J., Ersoy O., Norrby E., Persson M. A. A. 1996; Human antibodies from phage libraries: neutralizing activity against human immunodeficiency virus type 1 equally improved after expression as Fab and IgG in mammalian cells. European Journal of Immunology 26:3029–3034
     [Google Scholar]
  34. Scarselli E., Cerino A., Esposito G., Silini E., Mondelli M. U., Traboni C. 1995; Occurrence of antibodies reactive with more than one variant of the putative envelope glycoprotein (gp70) hypervariable region 1 in viremic hepatitis C virus-infected patients. Journal of Virology 69:4407–4412
     [Google Scholar]
  35. Schutten M., McKnight A., Huisman R. C., Thali M., McKeating J. A., Sodroski J., Goudsmit J., Osterhaus A. D. 1993; Further characterization of an antigenic site of HIV-1 gp120 recognized by virus neutralizing human monoclonal antibodies. AIDS 7:919–923
     [Google Scholar]
  36. Shimizu Y. K., Hijikata M., Iwamoto A., Alter H. J., Purcell R. H., Yoshikura H. 1994; Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses. Journal of Virology 68:1494–1500
     [Google Scholar]
  37. Shimizu Y. K., Igarashi H., Kiyohara T., Cabezon T., Farci P., Purcell R. H., Yoshikura H. 1996; A hyperimmune serum against a synthetic peptide corresponding to the hypervariable region 1 of hepatitis C virus can prevent viral infection in cell cultures. Virology 223:409–412
     [Google Scholar]
  38. Spaete R. R., Alexander D., Rugroden M. E., Choo Q. L., Berger K., Crawford K., Kuo C., Leng S., Lee C., Ralston R. and others 1992; Characterization of the hepatitis C virus E2/NS1 gene product expressed mammalian cells. Virology 188:819–830
     [Google Scholar]
  39. Widell A., Shev S., Månsson S., Zhang Y. Y., Foberg U., Norkrans G., Fryden A., Weiland O., Kurkus J., Nordenfelt E. 1994; Genotyping of hepatitis C virus isolates by a modified polymerase chain reaction assay using type specific primers: epidemiological applications. Journal of Medical Virology 44:272–279
     [Google Scholar]
  40. Zibert A., Schreier E., Roggendorf M. 1995; Antibodies in human sera specific to hypervariable region 1 of hepatitis C virus can block viral attachment. Virology 208:653–661
     [Google Scholar]
  41. Zibert A., Meisel H., Kraas W., Schulz A., Jung G., Roggendorf M. 1997; Early antibody response against hypervariable region 1 is associated with acute self-limiting infections of hepatitis C virus. Hepatology 25:1245–1249
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-81-10-2451
Loading
Recombinant human monoclonal antibodies against different conformational epitopes of the E2 envelope glycoprotein of hepatitis C virus that inhibit its interaction with CD81
J. Gen. Virol. 81, 2451 (2000); https://doi.org/10.1099/0022-1317-81-10-2451
/content/journal/jgv/10.1099/0022-1317-81-10-2451
/content/journal/jgv/10.1099/0022-1317-81-10-2451
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error